Prime Medicine Appoints Matthew Hawryluk as Chief Business Officer
[ad_1] Prime Medicine (Nasdaq: PRME) appointed Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer effective Nov 3, 2025. Dr. Hawryluk will lead corporate and business development, corporate…